Somatostatinoma

Somatostatinoma is a rare, malignant neuroendocrine tumor (NET) of the pancreatic islet cells, specifically the delta (D) cells, which secrete excessive amounts of somatostatin. This tumor is characterized by uncontrolled proliferation of D cells, leading to elevated circulating somatostatin levels that inhibit the secretion of numerous hormones (insulin, glucagon, growth hormone, cholecystokinin, secretin, gastrin, and pancreatic polypeptide) and exocrine pancreatic function. In veterinary medicine, somatostatinomas are exceedingly rare, with only isolated case reports in dogs and cats. They are classified as functioning or non-functioning based on clinical signs; functioning tumors produce clinical syndromes due to hormone excess, while non-functioning tumors present with mass effects. The tumor is typically located in the pancreas, but can also arise in the duodenum or other gastrointestinal sites. Somatostatinomas are often malignant, with metastasis to regional lymph nodes and liver at the time of diagnosis. The clinical syndrome, known as 'somatostatinoma syndrome', includes diabetes mellitus, cholelithiasis, steatorrhea, and hypochlorhydria, though these are rarely all present in veterinary patients. Early diagnosis is challenging due to nonspecific signs, and prognosis is generally guarded to poor.

The exact etiology of somatostatinoma is unknown, but it is believed to arise from neoplastic transformation of pancreatic D cells. Genetic mutations, such as those in the MEN1 (multiple endocrine neoplasia type 1) gene, are implicated in human somatostatinomas, but similar genetic predispositions have not been confirmed in veterinary species. Chronic inflammation, such as pancreatitis, may predispose to neuroendocrine tumor development, but evidence is lacking. No viral, bacterial, or environmental causes have been identified. In dogs and cats, the tumor is sporadic, with no clear breed or sex predilection. The molecular pathogenesis involves dysregulation of cell cycle control, apoptosis, and angiogenesis, leading to uncontrolled D cell proliferation and somatostatin hypersecretion.

Somatostatinoma is extremely rare in veterinary medicine. Only a few case reports exist in dogs and cats, with no large epidemiological studies. In humans, somatostatinomas account for less than 1% of all gastrointestinal neuroendocrine tumors, with an incidence of approximately 1 in 40 million. In dogs, pancreatic neuroendocrine tumors as a group are uncommon, representing less than 1% of all pancreatic neoplasms. No breed, age, or sex predilection has been consistently reported, but most cases occur in middle-aged to older animals (mean age 8-10 years). There is no geographic or seasonal variation. Due to the rarity, the true incidence is unknown, and many cases may be misdiagnosed as other pancreatic tumors or chronic pancreatitis.

Somatostatinomas secrete excessive somatostatin, a peptide hormone that inhibits the release of many hormones and exocrine secretions. The pathophysiology is primarily mediated by the inhibitory effects of somatostatin on the pituitary, pancreas, gastrointestinal tract, and gallbladder. Specifically, somatostatin inhibits insulin secretion, leading to hyperglycemia and diabetes mellitus; inhibits glucagon secretion, which may paradoxically worsen hypoglycemia in some cases; inhibits cholecystokinin and secretin, causing impaired gallbladder contraction and bile stasis, leading to cholelithiasis; inhibits pancreatic exocrine secretion, resulting in steatorrhea and malabsorption; and inhibits gastrin and gastric acid secretion, causing hypochlorhydria. Additionally, somatostatin inhibits growth hormone and thyroid-stimulating hormone, but these effects are less clinically relevant in animals. The tumor itself can cause local mass effects, including biliary obstruction, pancreatitis, and gastrointestinal obstruction. Malignant transformation leads to metastasis, most commonly to the liver and regional lymph nodes, contributing to systemic illness.

Predisposing factors for somatostatinoma are poorly understood due to the rarity. In humans, genetic syndromes such as multiple endocrine neoplasia type 1 (MEN1) and neurofibromatosis type 1 (NF1) are associated with somatostatinomas, particularly duodenal somatostatinomas in NF1. In veterinary patients, no specific genetic predispositions have been identified. Chronic pancreatitis may be a risk factor, as chronic inflammation can lead to neuroendocrine cell hyperplasia and neoplasia. Immunosuppression, either from disease or medication, may increase the risk of neoplasia in general, but no direct link has been established. Age is a risk factor, as most tumors occur in older animals. There is no evidence for dietary or environmental factors.

Clinical signs of somatostatinoma are often nonspecific and may be absent in non-functioning tumors. When present, they are related to the inhibitory effects of somatostatin and mass effect. The classic triad in humans includes diabetes mellitus, cholelithiasis, and steatorrhea, but this is rarely seen in animals. Common signs in dogs and cats include: weight loss, polyuria and polydipsia (due to diabetes mellitus), diarrhea (steatorrhea), vomiting, abdominal pain, jaundice (if biliary obstruction occurs), and palpable abdominal mass. In advanced cases, signs of metastatic disease, such as hepatomegaly, ascites, and lethargy, may be present. The onset is often insidious, and signs may be present for months before diagnosis. Physical examination may reveal a cranial abdominal mass, hepatomegaly, or icterus. Some animals may have concurrent pancreatitis, leading to acute abdominal pain and vomiting.

Differential diagnoses for somatostatinoma include: 1) Pancreatic adenocarcinoma: more common, presents with similar mass effects and metastasis, but lacks somatostatin hypersecretion; histopathology and immunohistochemistry (positive for somatostatin) differentiate. 2) Other pancreatic neuroendocrine tumors (insulinoma, gastrinoma, glucagonoma): clinical signs differ (hypoglycemia, hypergastrinemia, hyperglucagonemia), and hormone assays are diagnostic. 3) Chronic pancreatitis: causes similar abdominal pain, vomiting, and weight loss, but imaging shows diffuse pancreatic changes, and hormone levels are normal. 4) Exocrine pancreatic insufficiency (EPI): presents with steatorrhea and weight loss, but no mass on imaging, and serum trypsin-like immunoreactivity (TLI) is low. 5) Cholecystitis or cholelithiasis: causes jaundice and abdominal pain, but imaging shows gallbladder disease, not pancreatic mass. 6) Hepatic neoplasia: if metastasis is present, may mimic primary liver tumor; histopathology and immunohistochemistry are needed. 7) Inflammatory bowel disease (IBD): causes chronic diarrhea and weight loss, but no pancreatic mass on imaging. 8) Diabetes mellitus (uncomplicated): presents with polyuria/polydipsia, but no mass or steatorrhea.

The diagnostic approach for suspected somatostatinoma should be systematic: 1) Initial evaluation: complete history, physical examination, and baseline bloodwork (CBC, serum biochemistry, urinalysis). Look for hyperglycemia, elevated liver enzymes, and electrolyte imbalances. 2) Abdominal imaging: ultrasonography is the first-line imaging modality to identify a pancreatic mass, assess for metastasis (liver, lymph nodes), and evaluate the biliary system. If ultrasound is inconclusive, computed tomography (CT) or magnetic resonance imaging (MRI) may be used for better characterization. 3) Hormonal assays: measure serum somatostatin levels (if available) to confirm hypersecretion. In humans, elevated somatostatin levels are diagnostic, but this test is not routinely available in veterinary medicine. 4) Fine-needle aspiration (FNA) of the pancreatic mass or metastatic lesions for cytology and immunocytochemistry (positive for somatostatin, chromogranin A, synaptophysin). 5) Histopathology: surgical biopsy or post-mortem examination is the gold standard for definitive diagnosis. Immunohistochemistry for somatostatin, chromogranin, and synaptophysin confirms the neuroendocrine origin. 6) Staging: thoracic radiographs and abdominal ultrasound or CT to detect metastasis. 7) Additional tests: serum insulin, glucagon, gastrin, and pancreatic polypeptide levels to rule out other NETs. 8) Genetic testing for MEN1 mutations is not routinely performed in veterinary patients.

Hematology: Often unremarkable, but may show mild anemia of chronic disease or leukocytosis if inflammation is present. Serum biochemistry: Hyperglycemia is common due to diabetes mellitus; elevated liver enzymes (ALP, ALT) may indicate hepatic metastasis or biliary obstruction; hyperbilirubinemia if biliary obstruction; hypoalbuminemia due to malabsorption; electrolyte imbalances (e.g., hypokalemia) may occur with chronic diarrhea. Urinalysis: Glucosuria if diabetes mellitus; specific gravity may be low if diabetes insipidus-like effects (unlikely). Blood gas analysis: May show metabolic acidosis if diarrhea is severe. Specific biomarkers: Serum somatostatin levels are elevated, but this assay is not widely available. Chromogranin A (CgA) is a general neuroendocrine tumor marker and may be elevated. Pancreatic-specific lipase (cPLI or fPLI) may be elevated if concurrent pancreatitis. Serology/PCR: Not applicable. Endocrinological assays: Insulin levels may be low or normal; glucagon and gastrin levels may be low due to somatostatin inhibition. In humans, a secretin stimulation test can be used, but not in animals.

Radiography: Abdominal radiographs may reveal a soft tissue mass in the cranial abdomen, hepatomegaly, or choleliths (if mineralized). Thoracic radiographs are important for detecting pulmonary metastasis. Ultrasonography: The pancreatic mass appears as a well-defined, hypoechoic nodule or mass, often in the left or right lobe of the pancreas. The liver may show hypoechoic nodules if metastasis is present. Biliary dilation and choleliths may be seen. Doppler ultrasound can assess vascular invasion. Computed Tomography (CT): CT provides better contrast resolution and can detect small masses, assess vascular invasion, and stage metastasis. The tumor may show contrast enhancement. Magnetic Resonance Imaging (MRI): MRI is useful for evaluating the pancreas and surrounding soft tissues, but is less commonly used in veterinary practice. Endoscopy: Endoscopic ultrasound (EUS) can be used to evaluate the duodenum and pancreas, but is not widely available. Fluoroscopy: Not typically used. Echocardiography: Not directly relevant, but may be performed to rule out cardiac metastasis.

Fine Needle Aspiration (FNA): Cytology of the pancreatic mass typically shows clusters of small, round, uniform cells with a high nuclear-to-cytoplasmic ratio, salt-and-pepper chromatin, and occasional acinar or rosette formation. Immunocytochemistry can be performed on cell blocks for somatostatin, chromogranin A, and synaptophysin. Fluid analysis: If ascites is present, it is usually a modified transudate or exudate if metastasis is extensive. Histopathology: On biopsy, the tumor is composed of nests, trabeculae, or sheets of uniform neuroendocrine cells with round nuclei and finely granular eosinophilic cytoplasm. There is minimal pleomorphism and low mitotic index, but vascular invasion and metastasis may be present. Special stains: Immunohistochemistry is essential: positive for somatostatin, chromogranin A, synaptophysin, and neuron-specific enolase (NSE). Ki-67 proliferation index may be used to grade the tumor.

Treatment of somatostatinoma is primarily surgical resection if the tumor is localized and resectable. In dogs and cats, surgical removal of the pancreatic mass (partial pancreatectomy) is the treatment of choice, but it is often challenging due to the proximity to major vessels and the risk of pancreatitis. If metastasis is present, surgery may be palliative to relieve obstruction. Medical management focuses on controlling clinical signs: 1) Diabetes mellitus: insulin therapy (e.g., NPH insulin at 0.5-1.0 U/kg SC q12h, adjusted based on glucose curves). 2) Steatorrhea: pancreatic enzyme supplementation (e.g., pancreatic enzyme powder at 1 teaspoon per meal) and dietary management with low-fat, highly digestible diet. 3) Cholelithiasis: may require cholecystectomy if symptomatic. 4) Somatostatin analogs: Octreotide (a somatostatin analog) can be used to inhibit hormone secretion and reduce tumor growth, but its efficacy in veterinary patients is unproven. Dosage: 10-20 mcg/kg SC q8-12h, but use cautiously. 5) Chemotherapy: Limited evidence; options include streptozocin (500 mg/m² IV q3 weeks, with saline diuresis) or doxorubicin (30 mg/m² IV q3 weeks), but toxicity is significant. 6) Supportive care: antiemetics (e.g., maropitant 1 mg/kg SC q24h), gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h), and analgesics (e.g., buprenorphine 0.01-0.02 mg/kg SC q8-12h). 7) Radiation therapy: may be considered for palliative treatment of unresectable tumors, but is rarely used.

The prognosis for somatostatinoma is generally poor due to late diagnosis and high metastatic rate. In humans, the 5-year survival rate is approximately 60% for localized disease, but drops to 30% with metastasis. In veterinary patients, the prognosis is guarded to poor, with survival times ranging from weeks to months after diagnosis. Negative prognostic indicators include presence of metastasis at diagnosis, large tumor size, high Ki-67 index, and poor response to surgical resection. Animals that undergo complete surgical excision may have longer survival, but recurrence is common. Medical management can improve quality of life but does not cure the disease.

Post-treatment monitoring is essential. For animals that undergo surgical resection, re-check examinations should be performed every 1-3 months for the first year, then every 3-6 months thereafter. Monitoring should include: physical examination, body weight, serum biochemistry (glucose, liver enzymes, electrolytes), and abdominal ultrasound to detect recurrence or metastasis. If diabetes mellitus is present, serial blood glucose curves and fructosamine levels should be monitored. For animals receiving octreotide, monitor for adverse effects (e.g., diarrhea, vomiting) and adjust dose as needed. If chemotherapy is administered, monitor CBC and biochemistry for toxicity. Long-term management includes dietary modifications and pancreatic enzyme supplementation as needed.

Pearls: 1) Somatostatinoma should be considered in any middle-aged to older dog or cat with a pancreatic mass and concurrent diabetes mellitus or steatorrhea. 2) Immunohistochemistry is essential for definitive diagnosis; always request somatostatin staining on biopsy samples. 3) Octreotide can be used as a diagnostic test: if administration leads to improvement in clinical signs, it supports the diagnosis. 4) Surgical resection, if feasible, offers the best chance for prolonged survival. Pitfalls: 1) Misdiagnosing as pancreatic adenocarcinoma based on cytology alone; neuroendocrine tumors can look similar. 2) Overlooking metastasis on initial staging; always perform thoracic radiographs and abdominal ultrasound. 3) Failing to check serum somatostatin levels (if available) or other hormone levels, leading to missed diagnosis. 4) Using insulin without addressing the underlying tumor, which may lead to poor glycemic control. 5) Administering octreotide without monitoring for side effects, such as bradycardia or gastrointestinal upset.

Based on Plumb's Veterinary Drug Handbook, the following protocols may be considered: 1) Octreotide acetate: 10-20 mcg/kg SC q8-12h. Use with caution in animals with renal impairment. May cause diarrhea, vomiting, and bradycardia. 2) Insulin (NPH): initial dose 0.25-0.5 U/kg SC q12h, titrate based on glucose curves. Adjust for concurrent illness. 3) Pancreatic enzyme supplements: powder or tablet, 1 teaspoon per meal for dogs, 1/2 teaspoon for cats. Mix with food and allow to sit for 15-20 minutes before feeding. 4) Omeprazole: 0.5-1 mg/kg PO q12h, for gastric protection. 5) Maropitant: 1 mg/kg SC q24h, for vomiting. 6) Buprenorphine: 0.01-0.02 mg/kg SC q8-12h, for pain. 7) Streptozocin: 500 mg/m² IV q3 weeks, with saline diuresis (0.9% NaCl at 18 ml/kg/hr for 3 hours before and after). Monitor for nephrotoxicity and hepatotoxicity. 8) Doxorubicin: 30 mg/m² IV q3 weeks, with cardiac monitoring. 9) Prednisone: 0.5-1 mg/kg PO q12h, may be used for anti-inflammatory effects, but use cautiously due to diabetogenic effects.

Evidence for somatostatinoma in veterinary medicine is limited to case reports and small case series. A case report in a dog described a pancreatic somatostatinoma with metastasis to the liver, diagnosed via histopathology and immunohistochemistry. The dog was treated with surgical debulking and octreotide, but survived only 3 months. Another case in a cat presented with diabetes mellitus and a pancreatic mass; surgical excision was performed, and the cat survived 12 months without recurrence. In human medicine, somatostatinomas are well-characterized, and guidelines from the European Neuroendocrine Tumor Society (ENETS) recommend surgical resection for localized disease and somatostatin analogs for symptom control. There are no ACVIM or ECVIM consensus guidelines specific to somatostatinoma. The rarity of the disease precludes large clinical trials, and treatment recommendations are extrapolated from human medicine and other neuroendocrine tumors. Future research should focus on molecular characterization and targeted therapies.